180 related articles for article (PubMed ID: 34516351)
21. Knockdown of Long Non-Coding RNA XIST Inhibited Doxorubicin Resistance in Colorectal Cancer by Upregulation of miR-124 and Downregulation of SGK1.
Zhu J; Zhang R; Yang D; Li J; Yan X; Jin K; Li W; Liu X; Zhao J; Shang W; Yu T
Cell Physiol Biochem; 2018; 51(1):113-128. PubMed ID: 30439718
[TBL] [Abstract][Full Text] [Related]
22. Glycolysis is essential for chemoresistance induced by transient receptor potential channel C5 in colorectal cancer.
Wang T; Ning K; Sun X; Zhang C; Jin LF; Hua D
BMC Cancer; 2018 Feb; 18(1):207. PubMed ID: 29463225
[TBL] [Abstract][Full Text] [Related]
23. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
24. Sulforaphane suppresses carcinogenesis of colorectal cancer through the ERK/Nrf2‑UDP glucuronosyltransferase 1A metabolic axis activation.
Hao Q; Wang M; Sun NX; Zhu C; Lin YM; Li C; Liu F; Zhu WW
Oncol Rep; 2020 Apr; 43(4):1067-1080. PubMed ID: 32323779
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway.
Liu B; Liu Y; Zhao L; Pan Y; Shan Y; Li Y; Jia L
Mol Carcinog; 2017 Dec; 56(12):2669-2680. PubMed ID: 28767179
[TBL] [Abstract][Full Text] [Related]
27. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
[TBL] [Abstract][Full Text] [Related]
28. Silencing of CXCR7 gene represses growth and invasion and induces apoptosis in colorectal cancer through ERK and β-arrestin pathways.
Li XX; Zheng HT; Huang LY; Shi DB; Peng JJ; Liang L; Cai SJ
Int J Oncol; 2014 Oct; 45(4):1649-57. PubMed ID: 25051350
[TBL] [Abstract][Full Text] [Related]
29. LMTK3 is implicated in endocrine resistance via multiple signaling pathways.
Stebbing J; Filipovic A; Lit LC; Blighe K; Grothey A; Xu Y; Miki Y; Chow LW; Coombes RC; Sasano H; Shaw JA; Giamas G
Oncogene; 2013 Jul; 32(28):3371-80. PubMed ID: 22869149
[TBL] [Abstract][Full Text] [Related]
30. NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer.
Yang G; Huang L; Jia H; Aikemu B; Zhang S; Shao Y; Hong H; Yesseyeva G; Wang C; Li S; Sun J; Zheng M; Ma J
Oncogene; 2021 Oct; 40(41):5993-6006. PubMed ID: 34385595
[TBL] [Abstract][Full Text] [Related]
31. [ADAM17 knockdown increases sensitivity of SW480 cells to cetuximad].
Chen Y; Zheng K; Chen Z; Feng H; Fang W; Huang Z
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Nov; 38(11):1366-1371. PubMed ID: 30514687
[TBL] [Abstract][Full Text] [Related]
32. miR-199b-3p contributes to acquired resistance to cetuximab in colorectal cancer by targeting CRIM1 via Wnt/β-catenin signaling.
Han H; Li Y; Qin W; Wang L; Yin H; Su B; Yuan X
Cancer Cell Int; 2022 Jan; 22(1):42. PubMed ID: 35090460
[TBL] [Abstract][Full Text] [Related]
33. Delicaflavone induces ROS-mediated apoptosis and inhibits PI3K/AKT/mTOR and Ras/MEK/Erk signaling pathways in colorectal cancer cells.
Yao W; Lin Z; Shi P; Chen B; Wang G; Huang J; Sui Y; Liu Q; Li S; Lin X; Liu Q; Yao H
Biochem Pharmacol; 2020 Jan; 171():113680. PubMed ID: 31669234
[TBL] [Abstract][Full Text] [Related]
34. Knockdown of NIK and IKKβ-Binding Protein (NIBP) Reduces Colorectal Cancer Metastasis through Down-Regulation of the Canonical NF-κΒ Signaling Pathway and Suppression of MAPK Signaling Mediated through ERK and JNK.
Qin M; Zhang J; Xu C; Peng P; Tan L; Liu S; Huang J
PLoS One; 2017; 12(1):e0170595. PubMed ID: 28125661
[TBL] [Abstract][Full Text] [Related]
35. HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway.
Liu W; Zhang Z; Zhang Y; Chen X; Guo S; Lei Y; Xu Y; Ji C; Bi Z; Wang K
Cancer Biol Ther; 2015; 16(4):511-7. PubMed ID: 25778491
[TBL] [Abstract][Full Text] [Related]
36. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M
Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of ZNF278 arrests the cell cycle and decreases the proliferation of colorectal cancer cells via inhibition of the ERK/MAPK pathway.
Tian XQ; Guo FF; Sun DF; Wang YC; Yang L; Chen SL; Hong J; Fang JY
Oncol Rep; 2017 Dec; 38(6):3685-3692. PubMed ID: 29039562
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of CD147 promotes cell invasion, epithelial-to-mesenchymal transition and activates MAPK/ERK signaling pathway in colorectal cancer.
Xu T; Zhou M; Peng L; Kong S; Miao R; Shi Y; Sheng H; Li L
Int J Clin Exp Pathol; 2014; 7(11):7432-41. PubMed ID: 25550778
[TBL] [Abstract][Full Text] [Related]
39. Bcl-2-associated athanogene 3(BAG3) is associated with tumor cell proliferation, migration, invasion and chemoresistance in colorectal cancer.
Li N; Chen M; Cao Y; Li H; Zhao J; Zhai Z; Ren F; Li K
BMC Cancer; 2018 Aug; 18(1):793. PubMed ID: 30081850
[TBL] [Abstract][Full Text] [Related]
40. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
